In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

Treating Left Atrial Appendage Could Dampen Long Standing Persistent AF

LONDON, UK – In patients with long-standing persistent atrial fibrillation (AF) despite standard treatment, additional electrical isolation of an area called the left atrial appendage (LAA) can improve freedom from AF without increasing complications, results of the BELIEF study show.

Atrial Fibrillation
Arrhythmias and Device Therapy

EMBARGO : 30 August 2015 at 09:00 BST

The findings were presented today in a Hot Line session at ESC Congress 2015.

“Empirical left atrial appendage isolation, along with the standard approach of pulmonary vein isolation (PVI) and ablation of extra-pulmonary triggers is superior to the standard approach alone in enhancing the long-term success rate of catheter ablation,” reported investigator Luigi Di Biase, MD, PhD from Montefiore-Albert Einstein Center for Heart & Vascular Care, New York, USA and Texas Cardiac Arrhythmia Institute at St. David's Medical Center, Austin, Texas, USA.

“We first proposed in 2010 that the left atrial appendage was a relevant, under-reported trigger for AF, and now this trial confirms our findings,” he added.

 The study included 173 patents with “long-standing persistent” AF - defined as extending beyond one year.
Patients were randomly assigned to undergo standard treatment alone (PVI and ablation of extra-pulmonary triggers, n=88), or standard treatment plus the addition of LAA ablation (n=85).

For the primary endpoint of recurrence of AF at one year, 28% of standard treatment patients were recurrence-free compared to 56% of patients who had the additional LAA ablation (hazard ratio [HR] 1.92; p=0.001).

For patients who were not recurrence-free in either group, LAA isolation was performed in a second procedure.

At 24 months, after an average of 1.3 procedures, the cumulative success rate was 76% in the LAA ablation group and 56% in the standard treatment group. (HR 2.24; p= 0.003).

There was no difference in complication rates between groups at follow up, including transient ischemic attacks or strokes, however the mean radiofrequency time was longer in the LAA group (93 versus 77 minutes; P<0.001).

In multivariate analysis, no LAA ablation was associated with significantly higher recurrence of AF (HR 2.2; p = 0.004).

“It is logical to suggest that the LAA may initiate AF like the pulmonary veins because embryologically, the LAA grows out of the primordial LA, which is formed mainly by the adsorption of the primordial pulmonary veins and their branches,” explained Dr. Di Biase.

“In fact, an earlier study conducted by our group showed that LAA firing was the source of AF in 27% of patients and, after LAA ablation, 93% of those patients were AF free at long term follow up.”

-- END --

Notes to editor

SOURCES OF FUNDING: The study was sponsored by Texas Cardiac Arrhythmia Research Foundation.
Dr. Di Biase is a consultant for Biosense Webster, Stereotaxis and St Jude Medical and has received speaker honoraria/travel from Medtronic, Atricure, EPiEP, Boston Scientific and Biotronik.


The press conference timetable is available here
* Non Hot Line releases will be available under embargo on AlphaGalileo and EurekAlert a few days before ESC Congress. Hot Line releases will only be available when the embargo is lifted, online and on-site
* Information on Hot Line sessions is available here  

ESC Press Office
For background information or assistance, please contact the ESC Press Office.
For independent comment on site or interviews, please contact the ESC spokesperson coordinator: +44 7785 467 947

About the European Society of Cardiology
The European Society of Cardiology (ESC) represents more than 90 000 cardiology professionals across Europe and worldwide. Its mission is to reduce the burden of cardiovascular disease in Europe.
About ESC Congress 2015
ESC Congress is the world’s largest and most influential cardiovascular event contributing to global awareness of the latest clinical trials and breakthrough discoveries. ESC Congress 2015 takes place 29 August to 2 September at ExCel London in London, UK. Access the scientific programme. More information is available from the ESC Press Office at

To access all the scientific resources from the sessions during the congress, visit ESC Congress 365.  

This press release accompanies both a presentation and an ESC press conference at the ESC Congress 2015. Edited by the ESC from material supplied by the investigators themselves, this press release does not necessarily reflect the opinion of the European Society of Cardiology. The content of the press release has been approved by the presenter.